XML 78 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2023
Jan. 31, 2022
Aug. 31, 2018
May 31, 2018
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2018
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Other Commitments [Line Items]                    
Gain (loss) on strategic investment               $ 5,109 $ 3,542 $ 2,329
Restricted cash               5,770 5,770 5,770
Corporate Credit Card Program | Letter of Credit                    
Other Commitments [Line Items]                    
Restricted cash               2,000    
Fleet Program | Letter of Credit                    
Other Commitments [Line Items]                    
Restricted cash               400    
Other expense                    
Other Commitments [Line Items]                    
Gain (loss) on strategic investment               5,100 3,500 2,300
Stoke Therapeutics, Inc. | Research and development                    
Other Commitments [Line Items]                    
Mile stone payments payable   $ 907,500                
Upfront consideration and transaction costs   $ 60,000                
Cost splits description   For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits.                
License Agreements                    
Other Commitments [Line Items]                    
Upfront payment               102,500 $ 88,700 $ 11,000
License Agreements | North America                    
Other Commitments [Line Items]                    
Mile stone payments payable           $ 40,000        
License Agreements | Neuren | North America                    
Other Commitments [Line Items]                    
Upfront payment $ 100,000                  
Goodwill and Intangible Asset Impairment, Total           40,000        
PRV liability           $ 29,600        
Upfront license fee     $ 10,000              
License Agreements | Neuren | Research and development | North America                    
Other Commitments [Line Items]                    
Upfront payment         $ 100,000   $ 10,000      
License Agreements | Neuren | Development Commercialization and Sales Milestones                    
Other Commitments [Line Items]                    
Upfront payment 831,300                  
Exclusivity Deed | Neuren                    
Other Commitments [Line Items]                    
Aggregate carrying amount of strategic equity investment       $ 3,100            
Proceeds from sale of shares               $ 12,300    
Shares subscribed       1,330,000            
Shares sold of Neuren               1,330,000    
Exclusivity Deed | Neuren | Sales, general and administrative                    
Other Commitments [Line Items]                    
Payments for exclusive right       $ 900            
Maximum                    
Other Commitments [Line Items]                    
Mile stone payments payable               $ 3,400,000    
Maximum | License Agreements | Neuren | North America                    
Other Commitments [Line Items]                    
Mile stone payments payable $ 426,300   $ 455,000